Aztreonam/avibactam during continuous venovenous haemodiafiltration in a critically ill patient with NDM-producing Klebsiella pneumoniae: a case report and review of the literature - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Use of Aztreonam/Avibactam in Continuous Venovenous Haemodiafiltration for a Critically Ill Patient Infected with NDM-Producing Klebsiella pneumoniae: A Case Study and Literature Review

  • By

  • Federica Cosentino

  • Andrea Marino

  • Vittoria Moscatt

  • Mariagiovanna Coco

  • Pamela Prestifilippo

  • Alessandro Franzò

  • Bruno Cacopardo

  • Giuseppe Nunnari

  • September 11, 2026

Share

  • 1

    Carbapenem-resistant Enterobacterales infections, especially MBL-producing strains, present significant treatment challenges due to limited options.

  • 2

    Aztreonam/avibactam is a promising therapy for multidrug-resistant Gram-negative infections, providing stability against MBLs.

  • 3

    The pharmacokinetics of aztreonam/avibactam are altered during continuous renal replacement therapy, necessitating adjusted dosing.

  • 4

    A 76-year-old woman with NDM-producing Klebsiella pneumoniae was treated with aztreonam/avibactam during continuous venovenous haemodiafiltration.

  • 5

    Treatment was intensified with a continuous infusion protocol to maintain effective drug levels due to the patient's renal impairment.

Original Source(s)

Aztreonam/avibactam during continuous venovenous haemodiafiltration in a critically ill patient with NDM-producing Klebsiella pneumoniae: a case report and review of the literature

  • by Federica Cosentino, Andrea Marino, Vittoria Moscatt, Mariagiovanna Coco, Pamela Prestifilippo, Alessandro Franzò, Bruno Cacopardo, Giuseppe Nunnari

  • September 11, 2026

Related Content

Correction: Pathogen effects on the brain: the case of SARS-CoV-2 spike protein and neuro COVID

Musings from The Power List: Ali Tavassoli

Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology

The rationale for ophthalmic vigilance during the 2026 Hantavirus outbreak